Loading
journalsJournal
Molecular Cancer Therapeutics
AACR's preclinical therapeutics journal: where new small molecules, ADCs and combination strategies are first characterised in cells and mice.
Also called: Mol Cancer TherMCT
Overview
Molecular Cancer Therapeutics (Mol Cancer Ther, MCT) is the preclinical therapeutics journal of the American Association for Cancer Research (AACR), founded in 2001, appearing monthly and published by the society on a hybrid access model. It is where new small molecules, antibody-drug conjugates and combination strategies are first characterised in cells and mice, publishing preclinical pharmacology of new agents (including many ADC payload and linker studies), mechanism-of-action and resistance work, and companion-biomarker development. Its readers are drug discovery scientists and translational pharmacologists. Within OnCo it is linked from the Antibody-drug conjugate (ADC) entry and the Eric Haura biography, and a reader would use it for the preclinical evidence behind a new agent.
Publisher
American Association for Cancer Research · American Association for Cancer Research
Scope
drug discovery
Website
Access model
hybrid
Founded
2001
ISSN
1535-7163
review201894 citations
Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer
One of the most cited reviews Europe PMC returns for EZH2 in Ovarian cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
review20151,868 citations
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
One of the most cited reviews Europe PMC returns for PD-L1 in Bladder & urothelial cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
basic2014212 citations
Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect
One treatment page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Eric B. Haura
Associate Center Director for Clinical Science; Director, Lung Cancer Center of Excellence
Lung cancerProteomicsSignalling networks
Eric Haura is a lung cancer physician-scientist who maps drug-target signalling with proteomics.
Mark E. Burkard
Director, Holden Comprehensive Cancer Center, University of Iowa
Breast cancerCancer genomicsPrecision oncology
Breast cancer physician scientist who has directed the Holden Comprehensive Cancer Center at the University of Iowa since October 2024.
reviewMolecular Cancer Therapeutics 201894 citations
Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer
One of the most cited reviews Europe PMC returns for EZH2 in Ovarian cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
reviewMolecular Cancer Therapeutics 20151,868 citations
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
One of the most cited reviews Europe PMC returns for PD-L1 in Bladder & urothelial cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
basicMolecular Cancer Therapeutics 2014212 citations
Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect
One treatment page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.